Abstract:Introduction Acute myocardial infarction (AMI) induces a surge in inflammatory cytokines and cells including T helper cells (TH). TH17 cells are activated by pro-inflammatory cytokines such as IL-1, IL-6, and IL-21; they secrete IL-17 and IL-22 to promote neutrophil chemotaxis and to induce pro-inflammatory cytokine secretion from macrophages. Purpose We aimed to explore the prognostic value of the TH17 pathway and its component cytokines in AMI patients. Methods Patients with AMI (STEMI and NSTEMI) were included from the SPUM-ACS cohort (total N=4,787) selecting a time window <24 h from symptom onset to blood sampling before PCI. Patients with malignancies or immunosuppressive therapies were excluded. 160 patients who experienced death (N=85) or recurrent AMI (N=75) within 1-year follow-up (AMI-case) were compared to 152 counterparts with favorable outcome matched for age, sex, AMI subtype, and onset time (AMI-control). 45 healthy blood donors (HD) without cardiovascular disease were added as a reference group. Cytokine levels were reported as median + IQR and were analyzed with multivariate linear regression. Group comparisons were made using the Mann-Whitney U test or Kruskal-Wallis test and multiple comparisons corrected with Dunn's test. Kaplan-Meier curves were cut off at a median IL-22 level and tested with Log-rank test. Results Our measurement showed correlation among components in TH17 pathway. IL-22 was significantly associated with IL-1β (β=-3.027e-1, p=0.0164), IL-6 (β=5.413e-3, p<0.0001), and IL-21 (β=3.567e-2, p 0.05), percentage of women (23.8% vs 19.7%, p>0.05), and percentage of STEMI (70.6% vs 69.7%, p>0.05) did not differ between AMI-case and AMI-control. AMI-case and AMI-control both showed higher plasma IL-22 levels than HD, whereas there was no difference between AMI groups (Figure 1A). AMI patients who died within 1-year follow-up had higher IL-22 levels than those with recurrent AMI (Figure 1B). Regarding TH17 activation, patients who died had higher IL-17 levels (Figure 1C). Median IL-22 (4.86 pg/mL) levels were tested for predicting outcome: Patients with higher IL-22 levels had more risk for death or recurrent AMI (p=0.0253, Figure 2A). The mortality of patients above median IL-22 levels was higher than those below (p=0.0126); The KM-curves diverged early in less than 1 month after the initial event (Figure 2B). Conclusions Upstream regulators (IL-1β, IL-6) correlated with downstream effectors (IL-22, IL-17) within the pathways involving TH17 cells. Both IL-22 and Il-17 were higher in AMI patients who died within one year than in similar patients who survived. Investigating TH-17- and IL-22-related pathways may be of interest for further investigation in patients with AMI.

Dynamic Changes of Th17 Cell in Patients with Coronary Artery Disease

Dynamic Changes of Th1/Th2 Subsets in Patients with Acute Coronary Syndrome

Elevated Frequencies Of Circulating Th22 Cell In Addition To Th17 Cell And Th17/Th1 Cell In Patients With Acute Coronary Syndrome

Changes of Th1/Th2 Cell Ratio in the Peripheral Blood of Patients with Both Coronary Heart Disease and Diabetes

Role of Th1 and Th17 cells in the development and complexity of coronary artery disease: comparison analysis by the methods of flow cytometry and SYNTAX score

Relationship Between Serum Concentrations of IL-18, IL-10, IL-6 and Acute Coronary Syndrome

The Changes of Secretory Type Ⅱ Phospholipase A2 in Coronary Heart Disease and Its Relationship with High Sensifive-C Reactive Protein

Study on the Relationship between Serum Resistin and Acute Coronary Syndrome and Stable Angina Pectoris

Chemokine CXCL16 Expression in Serum of Patients with Coronary Artery Disease

Level of CD4~+ Foxp~(3+) Regulatory T Cells and Cytokines in Peripheral Blood of Patients with Coronary Heart Disease and Its Clinic Significance

Interleukin-17 and acute coronary syndrome

The Alteration of Circulating Dendritic Cells and Subtypes in ST-Elevated Acute Myocardial Infarction

Longitudinal Variations in Th and Treg Cells Before and After Percutaneous Coronary Intervention, and Their Intercorrelations and Prognostic Value in Acute Syndrome Patients

Interleukin-17-Producing CD4+ T Cells Promote Inflammatory Response and Foster Disease Progression in Hyperlipidemic Patients and Atherosclerotic Mice

Inflammatory Factors in the Serum of Patients with Acute Coronary Syndrome:Changes and Their Implications

Prognostic value of IL-22 levels and the TH17 pathway in patients with acute myocardial infarction

Gene expression pattern of TCR repertoire and alteration expression of IL-17A gene of γδ T cells in patients with acute myocardial infarction

Changes of Plasma Tissue Factor and Thrombin-Antithrombin Complex in Patients with Coronary Heart Disease

Disregulated expression of co-stimulatory molecules PD-1 and CD28 on peripheral T lymphocytes in patients with acute coronary syndrome

Changes of Peripheral Blood Levels of Total Immunoglobulin E in Patients with Coronary Heart Disease

Changes of Plasma Tissue Factor and Pathway Inhibitor in Patients with Coronary Heart Disease